Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tumors
Biotech
Immunome pays $50M for Ayala's phase 3 desmoid tumor drug
Two months after SpringWorks secured the first FDA approval for desmoid tumors, Immunome has bought a drug it claims could be more effective.
James Waldron
Feb 6, 2024 9:50am
HistoSonics scores $85M for tumor-blasting ultrasound
Dec 13, 2022 12:41pm
Boston Scientific acquires hydrogel maker Obsidio
Aug 15, 2022 10:31am
Hydrogels help predict how tissue characteristics affect cancer drug resistance
Oct 12, 2016 7:44am